Your email has been successfully added to our mailing list.

×
0 0 0 0 0 -0.00253567853149874 0.0047717523950104 -0.00436253626312606
Stock impact report

Alder BioPharmaceuticals® Presents New 12-Month Data of Eptinezumab in PROMISE 1 Phase 3 Trial Showing Long-Term Reduction in Episodic Migraine

ALDER BIOPHARMACEUTICALS INC (ALDR) 
Last alder biopharmaceuticals inc earnings: 8/6 04:07 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.alderbio.com/node/5806
Company Research Source: GlobeNewswire
- Data presented at AAN Annual Meeting demonstrate eptinezumab further reduces migraine risk following the third and fourth quarterly infusions - More than 50% of patients achieved a 75% reduction or greater of migraine days BOTHELL, Wash., April 24, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new twelve-month data from its PROMISE 1 Phase 3 clinical trial in episodic migraine patients. The data demonstrated that patients experienced even further reductions in migraine following the third and fourth quarterly infusions at both dose levels (100mg and 300mg) of eptinezumab, Alder’s lead investigational product candidate for migraine prevention targeting calcitonin gene-related peptide (CGRP). Detailed results will be presented today at the 70th Annual American Academy of Neurology Meeting in Los Angeles. “These results show eptinez Show less Read more
Impact Snapshot
Event Time:
ALDR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ALDR alerts
Opt-in for
ALDR alerts

from News Quantified
Opt-in for
ALDR alerts

from News Quantified